Epigenomics in hematopoietic transplantation: Novel treatment strategies

Epigenomics

Volumn 3, Issue 5, 2011, Pages 611-623

  Engel, Nicole ^a   Rank, Andreas ^a  

^a KLINIKUM AUGSBURG   (Germany)

Author keywords

allogeneic hematopoietic transplantation; alloreactivity; conditioning regimen; epigenetic regulation; graft versus host disease; graft versus leukemia effect; immunotolerance; regulatory T cells

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; GAMMA INTERFERON; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; PANOBINOSTAT; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; VORINOSTAT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADD ON THERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; AMYLOIDOSIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APLASTIC ANEMIA; AUTOIMMUNE DISEASE; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; CYTOKINE STORM; DNA METHYLATION; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; EPIGENETICS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENETIC REGULATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSTIMULATION; LEUKEMOGENESIS; LOW DRUG DOSE; MAINTENANCE THERAPY; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NATURAL KILLER CELL; NEUTROPENIA; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TRANSPLANTATION TOLERANCE; TREATMENT INDICATION;

AZACITIDINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; EPIGENOMICS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; T-LYMPHOCYTES, REGULATORY;

EID: 80054734165     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.11.80     Document Type: Review

References (99)

1. Taby R, Issa JP. Cancer epigenetics. CA Cancer J. Clin. 60(6), 376-392 (2010).
2. Jenuwein T, Allis CD. Translating the histone code. Science 293(5532), 1074-1080 (2001). (Pubitemid 32758077)
3. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72, 141-196 (1998). (Pubitemid 27435555)
4. Cedar H. DNA methylation and gene activity. Cell 53(1), 3-4 (1988).
5. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21(1), 103-107 (1999). (Pubitemid 29036293)
6. Steele N, Finn P, Brown R, Plumb JA. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br. J. Cancer 100(5), 758-763 (2009).
7. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 61(4), 1327-1333 (2001). (Pubitemid 34292551)
8. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59(2), 177-189 (2004). (Pubitemid 38481229)
9. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128(4), 683-692 (2007). (Pubitemid 46273572)
10. Martinez-Garcia E, Licht JD. Deregulation of H3K27 methylation in cancer. Nat. Genet. 42(2), 100-101 (2010).
11. Fenrick R, Hiebert SW. Role of histone deacetylases in acute leukemia. J. Cell Biochem. Suppl. 30-31, 194-202 (1998). (Pubitemid 29028741)
12. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435(7046), 1262-1266 (2005). (Pubitemid 40943093)
13. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96(15), 8681-8686 (1999). (Pubitemid 29354851)
14. Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J. Clin. Oncol. 28(4), 605-613 (2009).
15. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114(16), 3448-3458 (2009).
16. Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol. Oncol. Clin. North Am. 24(2), 317-330 (2010).
17. Damiani LA, Yingling CM, Leng S, Romo PE, Nakamura J, Belinsky SA. Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res. 68(21), 9005-9014 (2008).
18. Greco M, DAl F, Scardocci A, et al. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells Mol. Dis. 45(3), 181-185 (2010).
19. Koturbash I, Pogribny I, Kovalchuk O. Stable loss of global DNA methylation in the radiation-target tissue - a possible mechanism contributing to radiation carcinogenesis? Biochem. Biophys. Res. Commun. 337(2), 526-533 (2005). (Pubitemid 41429317)
20. Scardocci A, Guidi F, DAl F, et al. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br. J. Cancer 95(8), 1108-1113 (2006). (Pubitemid 44606840)
21. Hofmann WK, Takeuchi S, Takeuchi N, Thiel E, Hoelzer D, Koeffler HP. Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome. Leuk. Res. 30(11), 1347-1353 (2006). (Pubitemid 44307325)
22. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 59(15), 3730-3740 (1999). (Pubitemid 29381880)
23. Balkhi MY, Trivedi AK, Geletu M, et al. Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications. Oncogene 25(53), 7041-7058 (2006). (Pubitemid 44722072)
24. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363(25), 2424- 2433 (2010).
25. Rohrs S, Dirks WG, Meyer C, et al. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia. Mol. Cancer 8, 86 (2009).
26. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10), 3271-3279 (2006).
27. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66(12), 6361-6369 (2006).
28. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110(7), 2302-2308 (2007). (Pubitemid 47523148)
29. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP. 5-Aza-2′- deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64(4), 922-929 (1984).
30. Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R. Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2′-deoxycytidine. Lancet 2(8407), 867-868 (1984). (Pubitemid 14015488)
31. Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10(3), 176-182 (2005). (Pubitemid 40463154)
32. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study. Lancet Oncol. 10(3), 223-232 (2009).
33. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1), 52-57 (2007). (Pubitemid 46053042)
34. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10), 1247-1252 (2007). (Pubitemid 350106355)
35. Jacobson Lo ME, Robson Mj, Gaston Eo, Zirkle Re. Effect of spleen protection on mortality following x-irradiation. J. Lab. Clin. Med. 34, 1538-1543 (1949).
36. Lorenz E, Uphoff D, Reid TR, Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J. Natl Cancer Inst. 12(1), 197-201 (1951).
37. Little MT, Storb R. History of haematopoietic stem-cell transplantation. Nat. Rev. Cancer 2(3), 231-238 (2002). (Pubitemid 37328793)
38. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86(5), 2041-2050 (1995).
39. Mathé G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M. Adoptive immunotherapy of acute leukemia. experimental and clinical results. Cancer Res. 25(9), 1525-1531 (1965).
40. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300(19), 1068-1073 (1979). (Pubitemid 9198740)
41. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3), 756-763 (1998). (Pubitemid 28078275)
42. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol. Blood Marrow Transplant. 15(12), 1628-1633 (2009).
43. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation. focus on increasing use of unrelated donors. Bone Marrow Transplant. 39(2), 71-87 (2007). (Pubitemid 46085226)
44. Gratwohl A, Baldomero H, Frauendorfer K, Rocha V, Apperley J, Niederwieser D. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant. 41(8), 687-705 (2008). (Pubitemid 351587034)
45. Baldomero H, Gratwohl M, Gratwohl A, et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant. 46(4), 485-501 (2011).
46. Couban S, Barnett M. The source of cells for allografting. Biol. Blood Marrow Transplant. 9(11), 669-673 (2003). (Pubitemid 38145749)
47. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol. 23(24), 5675-5687 (2005).
48. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108(3), 1092-1099 (2006). (Pubitemid 44154650)
49. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15(2), 433-444 (1997). (Pubitemid 27074209)
50. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 373(9674), 1550-1561 (2009).
51. Sale GE, Lerner KG, Barker EA, Shulman HM, Thomas ED. The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am. J. Pathol. 89(3), 621-636 (1977).
52. Beschorner WE, Pino J, Boitnott JK, Tutschka PJ, Santos GW. Pathology of the liver with bone marrow transplantation. Effects of busulfan, carmustine, acute graft-versus-host disease, and cytomegalovirus infection. Am. J. Pathol. 99(2), 369-386 (1980). (Pubitemid 10116231)
53. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 80(12), 2964-2968 (1992). (Pubitemid 23004498)
54. Holler E. Cytokines, viruses, and graft-versus-host disease. Curr. Opin. Hematol. 9(6), 479-484 (2002). (Pubitemid 35191115)
55. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant. 11(12), 945-956 (2005). (Pubitemid 41754712)
56. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112(12), 4371-4383 (2008).
57. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9(9), 1144-1150 (2003). (Pubitemid 37173698)
58. Cao J, Chen C, Zeng L, Li L, Li Z, Xu K. Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation. Leuk. Res. 34(10), 1374-1382 (2010).
59. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4(4), 330-336 (2003). (Pubitemid 36432314)
60. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27(1), 20-21 (2001). (Pubitemid 32044513)
61. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 5(2), e38 (2007).
62. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13(11), 1299-1307 (2007). (Pubitemid 350073591)
63. Oliveira V, Sawitzki B, Chapman S, et al. Anti-CD4-mediated selection of Treg in vitro - in vitro suppression does not predict in vivo capacity to prevent graft rejection. Eur. J. Immunol. 38(6), 1677-1688 (2008).
64. Hoffmann P, Boeld TJ, Eder R, et al. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur. J. Immunol. 39(4), 1088-1097 (2009).
65. Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA, Riley JL. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS ONE 6(1), e15868 (2011).
66. Ma H, Lu C, Ziegler J, et al. Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J. Clin. Invest. 121(7), 2554-2569 (2011).
67. Marek N, Bieniaszewska M, Krzystyniak A, et al. The time is crucial for ex vivo expansion of T regulatory cells for therapy. Cell Transplant. DOI: 10.3727/096368911X566217 (2011) (Epub ahead of print).
68. Colonna M, Brooks EG, Falco M, Ferrara GB, Strominger JL. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 260(5111), 1121-1124 (1993). (Pubitemid 23186786)
69. Ciccone E, Pende D, Viale O, et al. Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition. definition of five distinct NK-determined allospecificities in humans. J. Exp. Med. 175(3), 709-718 (1992).
70. Kiessling R, Klein E, Wigzell H. Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 5(2), 112-117 (1975).
71. Pegram HJ, Ritchie DS, Smyth MJ, et al. Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leuk. Res. 35(1), 14-21 (2011).
72. Pende D, Spaggiari GM, Marcenaro S, et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias. evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 105(5), 2066-2073 (2005). (Pubitemid 40731793)
73. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562), 2097-2100 (2002). (Pubitemid 34229476)
74. Potter VT, Tindell VJ, Jeyaraj-Nallathambi L, et al. Retrospective analysis of 5-azacitidine as induction therapy prior to haematopoietic stem cell transplantation. Presented at: 37th Annual Meeting of the European Group for Blood and Marrow Transplantation. Paris, France, 3-6 April 2011 (Abstract P1172).
75. de Padua Silva L, de Lima M, Kantarjian H, et al. Outcome of allogeneic stem cell transplantation after hypomethylating therapy with 2′-deoxy-5 azacytidine for patients with myelodysplastic syndrome. Presented at: American Society of Hematology (ASH) 49th Annual Meeting and Exposition. Atlanta, Georgia, USA, 8-11 December 2007 (Abstract 1468).
76. de Lima M, Ravandi F, Shahjahan M, et al. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 97(5), 1242-1247 (2003). (Pubitemid 36237310)
77. Giralt S, Davis M, OBrien S, et al. Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia 11(Suppl. 1), S32-S34 (1997).
78. McCarty J, Shickle L, Roberts C, Candler K, Chung H. 5-Azacytidine prior to allogeneic transplantation effectively reduces relapse, TRM and overall mortality in high risk myelodysplasia and secondary AML. Presented at: 34th Annual Meeting of the European Group for Blood and Marrow Transplantation. Florence, Italy, 30 March-2 April 2008 (Abstract P746).
79. Lübbert M, Bertz H, Ruter BH, Mertelsmann RH, Finke J. Non-Intensive AML/MDS treatment with low-dose decitabine prior to reduced-intensity conditioning (RIC) and allogeneic blood stem cell transplantation of older patients. Presented at: American Society of Hematology (ASH) 48th Annual Meeting and Exposition. Orlando, Florida, USA, 9-12 December 2006 (Abstract 5257).
80. Wang X, Zhang W, Tripodi J, et al. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood 116(26), 5972-5982 (2010).
81. Morozova E, Rudnitskaya Y, Tretyakova M, Mamaev N, Gindiva T, Afanasyev B. Hypomethylating therapy with decitabine prior to allogeneic BMT for MDS/AML patients. Presented at: 37th Annual Meeting of the European Group for Blood and Marrow Transplantation. Paris, France, 3-6 April 2011 (Abstract P1173).
82. Czibere A, Graef T, Lind J, et al. 5-azacitidine in combination with donor lymphocyte infusions for the treatment of patients with MDS or AML relapsing after allogeneic stem cell transplantation. Presented at: American Society of Hematology (ASH) 48th Annual Meeting and Exposition. Orlando, Florida, USA, 9-12 December 2006 (Abstract 5341).
83. Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9), 1899-1905 (2009).
84. Platzbecker U, Wermke M, Radke J, et al. Efficiancy of 5-azacytidine in treating imminent relapse of patients with high-risk MDS or AML and minimal residual disease after allogeneic stem cell transplantation: results of the RELAZA trial. Presented at: 37th Annual Meeting of the European Group for Blood and Marrow Transplantation. Paris, France, 3-6 April 2011 (Abstract 0415).
85. Ravandi F, Kantarjian H, Cohen A, et al. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a Phase I study. Bone Marrow Transplant. 27(12), 1221-1225 (2001). (Pubitemid 32655389)
86. Schroeder T, Czibere A, Kröger N, et al. Azacytidine and donor lymphocyte infusions as first salvage treatment in patients with acute myeloid leukaemia or myelodysplastic syndromes relapsing after allogeneic stem cell transplantation: interim-analysis from the AZARELA-trial (NCT-00795548). Presented at: 37th Annual Meeting of the European Group for Blood and Marrow Transplantation. Paris, France, 3-6 April 2011 (Abstract 0414).
87. Leoni F, Zaliani A, Bertolini G, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl Acad. Sci. USA 99(5), 2995-3000 (2002). (Pubitemid 34240574)
88. Reddy P, Maeda Y, Hotary K, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl Acad. Sci. USA 101(11), 3921-3926 (2004). (Pubitemid 38381078)
89. Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 116(1), 129-139 (2010).
90. Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 115(1), 107-121 (2010).
91. de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116(23), 5420-5431 (2010).
92. Storb R. Can reduced-intensity allogeneic transplantation cure older adults with AML? Best Pract. Res. Clin. Haematol. 20(1), 85-90 (2007).
93. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11(1), 71-76 (2005). (Pubitemid 40215840)
94. Magner WJ, Kazim AL, Stewart C, et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 165(12), 7017-7024 (2000). (Pubitemid 32001174)
95. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11(1), 77-84 (2005). (Pubitemid 40215841)
96. Lübbert M, Bertz H, Wasch R, et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant. 45(4), 627-632 (2010).
97. Reddy P, Zou W. Blocking HDACs boosts regulatory T cells. Nat. Med. 13(11), 1282-1284 (2007). (Pubitemid 350073584)
98. Santourlidis S, Trompeter HI, Weinhold S, et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J. Immunol. 169(8), 4253-4261 (2002). (Pubitemid 35178197)
99. Chan HW, Kurago ZB, Stewart CA, et al. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J. Exp. Med. 197(2), 245-255 (2003). (Pubitemid 36152318)